SSc is clinically and aetiopathogenically heterogeneous. Consensus standards for more uniform trial design and selection of outcome measures are needed. The objective of this study was to develop evidence-based points to consider (PTCs) for future clinical trials in SSc.
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards
CUTOLO, MAURIZIO;
2015-01-01
Abstract
SSc is clinically and aetiopathogenically heterogeneous. Consensus standards for more uniform trial design and selection of outcome measures are needed. The objective of this study was to develop evidence-based points to consider (PTCs) for future clinical trials in SSc.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Twenty-two points.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
127.86 kB
Formato
Adobe PDF
|
127.86 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
